OSI Systems heads into the final stretch of September with shorts rebuilding, analysts cutting targets, and a stock that has lost more than 11% in a month — yet still trades at a meaningful discount to where the Street was positioned just weeks ago.
The short interest story is the week's clearest tension. Bears have added to positions aggressively: SI climbed 7.6% across the past five sessions to reach 12.1% of the free float, with virtually all of that move arriving in a single step on September 9, when short shares jumped from roughly 1.89 million to above 2.04 million and have held there. At 12% of float, this is a meaningfully elevated short book. Yet the lending market is not tight — availability is running at 220%, meaning there are more than two shares available to borrow for every share already lent out. That is well within the normal range, and the cost to borrow is just 0.51%, barely above the risk-free rate. Shorts are not being squeezed; they have ample room to press further if they choose. The ORTEX short score has drifted up to 68.7, its highest reading in the observable history here, consistent with that rebuilding trend.
Options are telling a quieter story than the short interest. The put/call ratio has crept higher over the past month — from lows near 0.09 in early August to 0.12 now — but remains almost exactly in line with its 20-day average, with a z-score of essentially zero. The 52-week high on PCR was 7.57, which puts the current reading in context: options traders are not particularly alarmed. The incremental shift toward protection has been gradual and measured, not a sharp defensive repositioning. Together with the loose availability, the positioning picture reads as cautious-but-not-crowded — shorts have added scale, but the conditions for a disorderly unwind are absent.
The Street has been steadily revising down. Following the most recent earnings print on August 20 — when the stock fell 6.4% on the day and shed a further 4.5% over the ensuing five sessions — analysts from B. Riley Securities and Oppenheimer both reiterated their positive ratings while cutting targets sharply, from $320 to $265 and $300 respectively. Bank of America had already trimmed to $300 from $315 in July. The consensus mean price target now sits at $281, implying roughly 39% upside from the current $202.59 close. That gap between price and target is wide enough to warrant a data-consistency check: the targets are current and the currency matches, so the divergence is genuine — it reflects a stock that has de-rated faster than analysts have been willing to follow. JP Morgan's Neutral rating with a $262 target is the outlier that captures the more skeptical end of the range; the majority of coverage remains at Buy or Outperform. The PE multiple has contracted by 2.2 points over the past 30 days to 16.1x, and the PB ratio has dropped nearly 0.8x over the same period — a valuation re-rating that has been swift. Factor scores add nuance: forward EPS growth expectations rank in the 91st percentile, one of the stronger readings in the universe, while short score rank (3rd percentile, meaning heavily shorted relative to peers) and days-to-cover rank (2nd percentile) underline the elevated short positioning.
The earnings track record is worth noting plainly. Both recent earnings events produced the same shape: down roughly 6.4% on day one, down another 4-5% by day five. The next print is scheduled for October 23. With shorts at 12% of float and the stock already pricing in meaningful disappointment relative to analyst targets, that date is the natural focal point for how the current tension resolves — whether the rebuilding short book proves prescient or faces a cover-driven reversal driven by the sizable discount to consensus.
See the live data behind this article on ORTEX.
Open OSIS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
